Showing results (41-50 of 110) with videos related to
Sort By:
Pageof 11
Molecular Medicine (Cambridge, Mass.)|November 29, 2002
An imidazoline compound completely counteracts interleukin-1[beta] toxic effects to rat pancreatic islet [beta] cellsGianpaolo Papaccio, Ferdinando Nicoletti, Francesco A Pisanti, et al.Scandinavian Journal of Gastroenterology|November 20, 2010
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's diseaseCasper Steenholdt, Klaus Bendtzen, Jørn Brynskov, et al.Cerebrovascular Diseases (Basel, Switzerland)|July 27, 2004
Serum cardiac troponin I in acute stroke is related to serum cortisol and TNF-alphaHanne Christensen, Helle Hjorth Johannesen, Anders Fogh Christensen, et al.Plos One|June 1, 2011
Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosisChris Juul Hedegaard, Christian Enevold, Finn Sellebjerg, et al.Journal of Periodontology|December 6, 2018
Pattern recognition receptor polymorphisms in early periodontitisFábio R M Leite, Christian Enevold, Klaus Bendtzen, et al.Journal of Periodontology|May 2, 2009
Decreased interleukin-2 responses to Fusobacterium nucleatum and Porphyromonas gingivalis in generalized aggressive periodontitisTanja Skuldbøl Borch, Morten Løbner, Klaus Bendtzen, et al.Clinical Immunology (Orlando, Fla.)|February 16, 2002
Prevention of murine experimental autoimmune orchitis by recombinant human interleukin-6Lu Li, Masahiro Itoh, Maila Ablake, et al.Journal of Periodontology|December 8, 2005
Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritisAnne Havemose-Poulsen, Lars Korsbaek Sørensen, Kaj Stoltze, et al.The American Journal of Gastroenterology|May 7, 2014
Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trialCasper Steenholdt, Klaus Bendtzen, Jørn Brynskov, et al.Arthritis and Rheumatism|November 30, 2006
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximabKlaus Bendtzen, Pierre Geborek, Morten Svenson, et al.Pageof 11